Dysregulated Lipid Metabolism Precedes Onset of Psychosis
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Dysregulated Lipid Metabolism Precedes Onset of Psychosis. / EU-GEI High Risk Study Group.
In: Biological Psychiatry, Vol. 89, No. 3, 01.02.2021, p. 288-297.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Dysregulated Lipid Metabolism Precedes Onset of Psychosis
AU - Dickens, Alex M.
AU - Sen, Partho
AU - Kempton, Matthew J.
AU - Barrantes-Vidal, Neus
AU - Iyegbe, Conrad
AU - Nordentoft, Merete
AU - Pollak, Thomas
AU - Riecher-Rössler, Anita
AU - Ruhrmann, Stephan
AU - Sachs, Gabriele
AU - Bressan, Rodrigo
AU - Krebs, Marie Odile
AU - Amminger, G. Paul
AU - de Haan, Lieuwe
AU - van der Gaag, Mark
AU - Valmaggia, Lucia R.
AU - Hyötyläinen, Tuulia
AU - McGuire, Philip
AU - Calem, Maria
AU - Tognin, Stefania
AU - Modinos, Gemma
AU - Velthorst, Eva
AU - Kraan, Tamar C.
AU - van Dam, Daniella S.
AU - Burger, Nadine
AU - Nelson, Barnaby
AU - McGorry, Patrick
AU - Pantelis, Christos
AU - Politis, Athena
AU - Goodall, Joanne
AU - Borgwardt, Stefan
AU - Rapp, Charlotte
AU - Ittig, Sarah
AU - Studerus, Erich
AU - Smieskova, Renata
AU - Gadelha, Ary
AU - Brietzke, Elisa
AU - Asevedo, Graccielle
AU - Asevedo, Elson
AU - Zugman, Andre
AU - Domínguez-Martínez, Tecelli
AU - Racciopi, Anna
AU - Kwapil, Thomas R.
AU - Monsonet, Manel
AU - Rosa, Araceli
AU - Frajerman, Ariel
AU - Chaumette, Boris
AU - Bourgin, Julie
AU - Nordholm, Dorte
AU - Glenthøj, Birte
AU - EU-GEI High Risk Study Group
N1 - Publisher Copyright: © 2020 Society of Biological Psychiatry
PY - 2021/2/1
Y1 - 2021/2/1
N2 - Background: A key clinical challenge in the management of individuals at clinical high risk for psychosis (CHR) is that it is difficult to predict their future clinical outcomes. Here, we investigated if the levels of circulating molecular lipids are related to adverse clinical outcomes in this group. Methods: Serum lipidomic analysis was performed in 263 CHR individuals and 51 healthy control subjects, who were then clinically monitored for up to 5 years. Machine learning was used to identify lipid profiles that discriminated between CHR and control subjects, and between subgroups of CHR subjects with distinct clinical outcomes. Results: At baseline, compared with control subjects, CHR subjects (independent of outcome) had higher levels of triacylglycerols with a low acyl carbon number and a double bond count, as well as higher levels of lipids in general. CHR subjects who subsequently developed psychosis (n = 50) were distinguished from those that did not (n = 213) on the basis of lipid profile at baseline using a model with an area under the receiver operating curve of 0.81 (95% confidence interval = 0.69–0.93). CHR subjects who became psychotic had lower levels of ether phospholipids than CHR individuals who did not (p <.01). Conclusions: Collectively, these data suggest that lipidomic abnormalities predate the onset of psychosis and that blood lipidomic measures may be useful in predicting which CHR individuals are most likely to develop psychosis.
AB - Background: A key clinical challenge in the management of individuals at clinical high risk for psychosis (CHR) is that it is difficult to predict their future clinical outcomes. Here, we investigated if the levels of circulating molecular lipids are related to adverse clinical outcomes in this group. Methods: Serum lipidomic analysis was performed in 263 CHR individuals and 51 healthy control subjects, who were then clinically monitored for up to 5 years. Machine learning was used to identify lipid profiles that discriminated between CHR and control subjects, and between subgroups of CHR subjects with distinct clinical outcomes. Results: At baseline, compared with control subjects, CHR subjects (independent of outcome) had higher levels of triacylglycerols with a low acyl carbon number and a double bond count, as well as higher levels of lipids in general. CHR subjects who subsequently developed psychosis (n = 50) were distinguished from those that did not (n = 213) on the basis of lipid profile at baseline using a model with an area under the receiver operating curve of 0.81 (95% confidence interval = 0.69–0.93). CHR subjects who became psychotic had lower levels of ether phospholipids than CHR individuals who did not (p <.01). Conclusions: Collectively, these data suggest that lipidomic abnormalities predate the onset of psychosis and that blood lipidomic measures may be useful in predicting which CHR individuals are most likely to develop psychosis.
KW - At-risk mental state
KW - Clinical high risk for psychosis
KW - Lipid metabolism
KW - Lipidomics
KW - Mass spectrometry
KW - Schizophrenia
U2 - 10.1016/j.biopsych.2020.07.012
DO - 10.1016/j.biopsych.2020.07.012
M3 - Journal article
C2 - 32928501
AN - SCOPUS:85097451775
VL - 89
SP - 288
EP - 297
JO - Biological Psychiatry
JF - Biological Psychiatry
SN - 0006-3223
IS - 3
ER -
ID: 285388408